HK Stock Market Move | LEPU BIO-B(02157) rose over 7% in the afternoon, and CDH17-targeting ADC has been approved for clinical trials. The drug had already been granted overseas authorization earlier this year.

LEPU BIO-B (02157) rose more than 7% in the afternoon, up 5.45% as of press time, closing at HK$5.61, with a turnover of HK$94.05 million. On the news front, on June 12, China's National Medical Products Administration Drug Evaluation Center official website announced that Lepu Biopharma's class 1 new drug MRG007 has been approved for clinical trials, aiming to develop treatments for localized advanced or metastatic solid tumors. Public information shows that MRG007 is an ADC targeting CDH17, formed by the site-specific coupling of the novel humanized IgG1 antibody with the cytotoxin Exatecan, with a balanced drug-to-antibody ratio (DAR). This differentiated design is expected to enhance anti-tumor efficacy and broaden the treatment window. It is worth noting that in January of this year, ArriVent BioPharma and Lepu Biopharma announced a global exclusive licensing agreement, granting ArriVent the exclusive rights to develop, manufacture, and commercialize MRG007 outside of Greater China. Lepu Biopharma will receive a one-time upfront payment of $47 million and near-term milestone payments, as well as milestone payments of up to $1.16 billion for development, registration, and sales.